$7.30
-0.10 (-1.35%)
Orexigen Therapeutics, Inc. (OREX)
CAPS Rating:
A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.
RSS Headlines
Fool UK
Recs
OREX management panicked and accepted any horrible deal to get their hands on some cash. But there are a whole host of medical, technology, finance, manufacturing and retail names out there that are starving for capital. And you better believe that once the next window opens in the coming weeks, most likely underwriters will be falling all over themselves to bring these guys to market and collect their fat fees.
This is fall down to ZERO!